{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:19:43Z","timestamp":1777389583791,"version":"3.51.4"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"KBP Biosciences"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,1,18]]},"abstract":"<jats:p>KBP-7072 is a novel broad-spectrum tetracycline (aminomethylcycline) antibacterial in clinical development (oral and intravenous formulations) for the treatment of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections. KBP-7072 is active against many of the World Health Organization priority pathogens.<\/jats:p>","DOI":"10.1128\/aac.01397-21","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T17:20:05Z","timestamp":1633972805000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-9019","authenticated-orcid":true,"given":"Michael D.","family":"Huband","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer D.","family":"Thompson","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabina D.","family":"Gurung","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingmei","family":"Liu","sequence":"additional","affiliation":[{"name":"KBP Biosciences Co., Ltd., Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"KBP Biosciences Co., Ltd., Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Zhang","sequence":"additional","affiliation":[{"name":"KBP Biosciences USA, Inc., Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-6308","authenticated-orcid":true,"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":true,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/367622"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1368-7646(02)00051-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025387"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.01.022"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Kaminishi T Schedlbauer A Ochoa-Lizarralde B de Astigarraga E Capuni R Yang F Benn V Liu Q Tan X Zhang M Connell SR Fucini P. 2018. The third-generation tetracycline KBP-7072 exploits and reveals a new potential of the primary tetracycline binding pocket. bioRxiv doi:10.1101\/508218:508218.","DOI":"10.1101\/508218"},{"key":"e_1_3_2_7_2","volume-title":"Antibacterial activity of KBP-7072 against clinical isolates of drug-resistant bacteria, Abstr Mondy-565.","author":"Wang Y","year":"2016","unstructured":"Wang Y, Liu Q, Zhang B. 2016. Antibacterial activity of KBP-7072 against clinical isolates of drug-resistant bacteria, Abstr Mondy-565. ASM Microbe, June 16\u201320, Boston, MA, USA."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02375-19"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02488-19"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115054"},{"key":"e_1_3_2_11_2","unstructured":"ClinicalTrials.gov. 2015. Safety tolerability and pharmacokinetics of KBP-7072. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02454361. Accessed November 2018."},{"key":"e_1_3_2_12_2","unstructured":"ClinicalTrials.gov. 2016. A multiple ascending dose study of KBP-7072 in healthy subjects. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02654626. Accessed November 2019."},{"key":"e_1_3_2_13_2","unstructured":"ClinicalTrials.gov. 2020. A multiple ascending dose study to investigate safety of KBP-7072 in healthy subjects. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04532957. Accessed March 2021."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02404-18"},{"key":"e_1_3_2_15_2","unstructured":"WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research discovery and development of new antibiotics. http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Accessed March 2021."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0267-8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy293"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1544"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.662"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00488-20"},{"key":"e_1_3_2_22_2","unstructured":"Paratek Pharmaceuticals Inc. 2018. Nuzyratm (omadacycline). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf. Accessed 22 March 2021."},{"key":"e_1_3_2_23_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 30th informational supplement.","author":"CLSI.","year":"2020","unstructured":"CLSI. 2020. Performance standards for antimicrobial susceptibility testing: 30th informational supplement. M100Ed30. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_24_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically.","author":"CLSI.","year":"2018","unstructured":"CLSI. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M07Ed11. Approved standard, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_25_2","unstructured":"USFDA. 2020. Antibacterial susceptibility test interpretive criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria. Accessed March 2021."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01397-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01397-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:35:45Z","timestamp":1645486545000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01397-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,18]]}},"alternative-id":["10.1128\/AAC.01397-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01397-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"2021-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01397-21"}}